Catálogo de publicaciones - revistas
Hepatology
Resumen/Descripción – provisto por la editorial en inglés
The premier publication in the field of liver disease, Hepatology publishes original, peer-reviewed articles concerning all aspects of liver structure, function and disease. Each month, the distinguished Editorial Board monitors and selects only the best articles on subjects such as immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism.Palabras clave – provistas por la editorial
Hepatology; Hepatitis; Cirrhosis; Liver; Gastroenterology; Immunology
Disponibilidad
| Institución detectada | Período | Navegá | Descargá | Solicitá |
|---|---|---|---|---|
| No detectada | desde ene. 1981 / hasta dic. 2022 | Wiley Online Library |
Información
Tipo de recurso:
revistas
ISSN impreso
0270-9139
ISSN electrónico
1527-3350
País de edición
Estados Unidos
Fecha de publicación
1981-
Cobertura temática
Tabla de contenidos
Pediatric and adult forms of type I autoimmune hepatitis in argentina: Evidence for differential genetic predisposition
Marcelo Pando; Julian Larriba; Gabriela C. Fernandez; Hugo Fainboim; Mirta Ciocca; Margarita Ramonet; Isabel Badia; Jorge Daruich; Jorge Findor; Hugo Tanno; Cristina Cañero-Velasco; Leonardo Fainboim
<jats:sec> <jats:title/> <jats:p>The aim of this study was to compare major histocompatibility complex (MHC) class II susceptibility to type 1 autoimmune hepatitis (AH) between children and adults of the same ethnic group. HLA-DRB1, HLA-DRB3, HLA-DQA1, and HLA-DQB1 gene subtypes were examined by high resolution oligonucleotide typing in 122 pediatric (PAH) and 84 adult (AAH) patients and in 208 controls. In children, HLA-DRB1*1301 was the primary susceptibility allele (66.4% patients vs. 10.6% controls, relative risk [RR] = 16.3, <jats:italic toggle="yes">P</jats:italic>c < 10<jats:sup>−24</jats:sup>) whereas HLA-DRB1*1302, which differs from HLA-DRB1*1301 by only 1 amino acid, appeared to be protective. The exclusion of individuals with HLA-DRB1*1301 from control and pediatric patients allowed us to find a secondary association of PAH with HLA-DRB1*0301. Possession of HLA-DRB1*1301, however, was associated with a lower therapeutic response rate. Analysis of peptide binding pocket residues indicated that Tyr 10, Ser 11, Ser 13, and Val 86 in the class II β chain were present in 85% of patients compared with 37% of controls, suggesting that a high proportion of AH susceptibility is attributable to these residues (etiologic fraction [EF] = 76%). In contrast to the class II associations in children, AAH was associated with HLA-DRB1*0405 (RR = 10.4, <jats:italic toggle="yes">P</jats:italic>c < .005) but not with HLA-DRB1*1301 or HLA-DRB1*0301. In addition, HLA-DR4 with the class I gene, HLA-A11, appeared synergistic in predisposing AAH patients to develop extra-hepatic autoimmune (AI) manifestations (odds ratio [OR] = 104.9, <jats:italic toggle="yes">P</jats:italic>c < 10<jats:sup>−4</jats:sup>). Concomitant differences in autoantibody profiles were also observed in PAH versus AAH: smooth muscle antibodies (SMA) were most prevalent in PAH but antinuclear antibodies were most prevalent in AAH (<jats:italic toggle="yes">P</jats:italic> = .003). This study therefore reveals that different HLA-DRB1 allotypes confer susceptibility to AH in children and adults and raises the possibility that PAH and AAH may be triggered by different factors.</jats:p> </jats:sec>
Pp. 1374-1380
doi: 10.1002/hep.26987
Chronic hepatitis E virus infection beyond transplantation or human immunodeficiency virus infection
Christoph Höner zu Siederdissen; Sven Pischke; Jerome Schlue; Katja Deterding; Timo Hellms; Susanne Schuler-Lüttmann; Anke Schwarz; Michael P. Manns; Markus Cornberg; Heiner Wedemeyer
Palabras clave: Hepatology.
Pp. 1112-1113
doi: 10.1002/hep.27556
Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity
Silvia Sookoian; Gustavo O. Castaño; Romina Scian; Pablo Mallardi; Tomas Fernández Gianotti; Adriana L. Burgueño; Julio San Martino; Carlos J. Pirola
Pp. 515-525
doi: 10.1002/hep.27581
Sofosbuvir modulates the intimate relationship between hepatitis C virus and lipids
Manuel Romero‐Gómez; Ángela Rojas
Pp. 744-747
doi: 10.1002/hep.27584
The continuum of hepatitis C testing and care
Kendra Viner; Danica Kuncio; E. Claire Newbern; Caroline C. Johnson
Pp. 783-789
doi: 10.1002/hep.27990
Is hepatitis E virus an emerging problem in industrialized countries?
Ibrahim M. Sayed; Ann-Sofie Vercouter; Sayed F. Abdelwahab; Koen Vercauteren; Philip Meuleman
Palabras clave: Hepatology.
Pp. 1883-1892
doi: 10.1002/hep.28227
Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs
Anthony Cousien; Viet Chi Tran; Sylvie Deuffic-Burban; Marie Jauffret-Roustide; Jean-Stéphane Dhersin; Yazdan Yazdanpanah
Pp. 1090-1101
doi: 10.1002/hep.32148
Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice
Jingjing Duan; Zhuo Wang; Ran Duan; Chenxinhui Yang; Ruolin Zhao; Qi Feng; Yuanyuan Qin; Jingwei Jiang; Shouyong Gu; Kaiyan Lv; Libo Zhang; Bixia He; Lutz Birnbaumer; Song Yang; Zhen Chen; Yong Yang
Palabras clave: Hepatology.
Pp. 140-153